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Summary
Since the arrival of several new antivirals and
due to the growing molecular and clinical knowl-
edge of hepatitis B virus (HBV) infection, therapy
of hepatitis B has become complex.Clinical guide-
lines aim at streamlining medical attitudes: in this
respect, the European Association for the Study of the
Liver (EASL) recently issued clinical practice
guidelines for the management of chronic hepati-
tis B. Guidelines made by international experts
need however to be adapted to local health care
systems.Here, we summarise the EASL guidelines
with some minor modifications in order to be
compatible with the particular Swiss situation,
while discussing in more detail some aspects.
Chronic hepatitis B is a complex disease with sev-
eral phases where host and viral factors interact:
the features of this continuous interplay need to
be evaluated when choosing the most appropriate
treatment. The EASL guidelines recommend, as
first-line agents, using the most potent antivirals
available with the optimal resistance profile, in or-
der to abate HBV DNA as rapidly and as sustain-
ably as possible. Once therapy has been started,
the infection evolves and resistant viral strains may
emerge. Rescue therapy needs to be started early
with more potent agents lacking cross-resistance.
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Introduction
Over the last decades several guidelines for
the treatment of chronic hepatitis due to the hep-
atitis B virus (HBV), or chronic hepatitis B (CHB),
have been issued by many organisations and ex-
pert panels aimed at defining diagnostic criteria
and guiding decisions regarding the management
of CHB.These documents aim at streamlining the
current attitude in dealing with HBV infection
and disease, based on currently available evidence.
The guideline-based approach to healthcare is rel-
atively recent, its objectives being to standardise
medical care, to improve its quality, reduce risks
and achieve the best balance between cost and
medical effectiveness. However, guidelines are
often issued at international level and thus may
need to be adapted to local healthcare systems [1].
In this review, we will summarise the consensus
statements and algorithms of the recently issued
EASL clinical practice guidelines for the manage-
ment of chronic hepatitis B [2] with some adapta-
tions due to the peculiar Swiss context.
HBV infection can cause chronic liver infec-
tion and hepatitis and is a global public health
problem. Worldwide, about two billion people
have been infected with HBV, of whom over 350
million are currently, chronically infected, ac-
counting for about 700000 deaths per year [3]. In
Switzerland, about 6.5% of the population has
been infected with HBV, with an estimated 20000
cases presently suffering from CHB [4]. The an-
nual incidence of HBV-related hepatocellular car-
cinoma (HCC) is high, i.e. between 2 and 5%,
once cirrhosis is established [5]. In addition, the
global and the local Swiss epidemiology of HBV is
continually evolving, due to population migration,
essentially from high to low endemicity countries.
When approaching HBV therapy, one should
consider that CHB is a dynamic infection with five
major phases (table 1), each of them potentially
lasting for years or even decades. The correct
appreciation of these phases is fundamental for
the treatment of CHB. Schematically, HBV infec-
tion proceeds from a HBeAg-positive phase to a
HBeAg-negative one. HBeAg-positive chronic
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HBV infection presents usually with high levels of
viral replication and infectivity: liver disease can
be mild or nil, reflecting host immune tolerance.
Then, spontaneous seroconversion from HBeAg
to anti-HBe may occur, usually accompanied by
a hepatitis flare-up. This is characertised by in-
creased serum transaminases and inflammatory
infiltrates of liver lobules and decreasing viraemia
levels, signalling the attempt of the host immune
response to eliminate HBV-infected hepatocytes.
If efficacious, this immune elimination may evolve
towards a phase of inactive HBV carriage, with
stably normal transaminases, no or minimal liver
damage, and low to undetectable HBV DNA.
HBeAg seroconversion is a commonly accepted,
surrogate end-point of treatment outcome, since
it is associated with improved prognosis.However,
evolution towards a distinct entity, namely
HBeAg-negative chronic hepatitis B, is also possi-
ble. This is associated with mutations in the HBV
genome, preventing the virus from secreting
HBeAg, and is characterised by fluctuating
transaminases, lower HBV DNA levels and some-
times progressive disease.The choice of treatment
differs according to the phase of infection, and will
be discussed below.Recently,moreover, eight gen-
otypes of HBV have been identified (A through
H). Growing evidence shows that the natural his-
tory and treatment response may differ depending
on the infecting HBV genotype. In general, geno-
type A is associated with better response to inter-
feron treatment, with higher HBeAg seroconver-
sion rates (47%) than genotype B (44%), genotype
C (28%) or D (25%) [7]. Also disease progression
seems to vary according to genotypes, since it
appears to be slower in genotype B than in C [8],
whereas genotype C and certain subtypes of B ap-
pear to be associated with a higher risk of develop-
ing cirrhosis and HCC [9]. However, further data
are warranted before HBV genotyping can be rec-
ommended for clinical decision making.
Table 1
Phases of chronic
HBV infection.
Phases of
infection
HBsAg HBV DNA ALT levels Histology Comments
Immune tolerant Positive High levels Normal Mild or no
necro-inflammation
Usually perinatally or early-in-
life infected patients
Immune reactive Positive Low levels Increased and/
or fluctuating
Moderate to severe
necro-inflammation
HBeAg is usually positive but
seroconversion with HBeAg
loss may occur. Progression to
fibrosis is increased. Increased
risk for HCC
Inactive carrier
state
Positive Very low or undetectable Normal Mild or no
necro-inflammation
HBeAg is negative
HBeAg negative Positive Fluctuating levels Increased,
often
fluctuating
Moderate to severe
necro-inflammation
Lack of HBeAg secretion.
Increased risk of cirrhosis
and HCC
HBsAg-negative
or past infection
Negative Negative (minimal
levels, i.e. <200 IU/ml,
may indicate an occult
infection)
Normal No necro-inflammation Anti-HBc with or without
anti-HBs. Immunosuppression
may reactivate viral replication
Table 2
Pre-treatment
assessment of liver
disease.
Biochemical markers: AST, ALT, gGT, AP, serum albumin
prothrombin time, blood count
Full HBV serology: HBsAg, HBeAg, anti-HBe, anti-HBc
and anti-HBs
Serum HBV DNA: quantitative measurement expressed in
IU/ml
Screening for other causes of chronic liver disease: HDV, HCV,
HIV, autoimmune, alcoholic and metabolic liver disease (steatosis)
Ultrasound examination of the upper abdomen
Liver biopsy: either if abnormal ALT or HBV DNA >2000 IU/ml
(or both)
Table 3
Indication for the
treatment of CHB.
Serum ALT levels > upper level of the norm
HBV DNA >2000 IU/ml
(except in patients in the immune tolerant phase)
Moderate to severe active necro-inflammation (≥A2) and/or
fibrosis (≥F2 in the METAVIR score) at liver histology
Compensated cirrhosis and detectable HBV DNA: treatment
should be considered even in case of normal ALT levels and/or
low HBV DNA (≤2000 IU/ml)
Decompensated cirrhosis: rapid, profound suppression of HBV
DNA is mandatory independently of other parameters
Indication for treatment: who needs to be treated and why?
Chronic infection with HBV does not neces-
sarily mean chronic liver disease. Thus, the accu-
rate assessment of the appropriate markers over an
appropriate time period (at least two laboratory
tests over 12 months) is fundamental to establish a
correct diagnosis and the indication for treatment.
Thus, prior to starting antiviral therapy, the sever-
ity of liver disease should be assessed, and any po-
tential co-morbidity should be ruled out (table 2).
A complex and still controversial issue is the role
of the liver biopsy in CHB. Liver biopsy is an in-
vasive procedure primarily aimed at determining
the degree of inflammation and fibrosis. The
EASL guidelines recommend performing a biopsy
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either when ALT levels are abnormal or when
serum HBV DNA levels are above 2000 IU/ml.
Moreover, a liver biopsy is not deemed necessary
if treatment is indicated regardless of liver histol-
ogy or in case of clinical evidence of cirrhosis.
However, it remains an open question, whether
patients in the “immune tolerant” phase (e.g. peri-
natally infected patients) should undergo biopsy.
Such patients present with no or only mild necro-
inflammation without fibrosis [6].Thus, a liver bi-
opsy is unlikely to change the treatment decision
in patients whomight not be eligible for treatment
anyway.
Indication for therapy is based on the combi-
nation of three criteria: 1) serum HBV DNA lev-
els; 2) serum aminotransferase levels and 3) his-
tological grade and stage (table 3). Thus, treat-
ment is indicated when serum ALT levels are
above the upper limit of normal (ULN) and/or
liver biopsy shows moderate to severe necro-in-
flammation and/or fibrosis (≥A2 and/or ≥F2 in the
METAVIR score) and/or HBV DNA is above
2000 IU/ml (or 10000 copies/ml), with the nota-
ble exception of patients in the immune tolerant
phase. Decision making co-factors for therapy are
the patient’s age and health status and whether the
patient will have continuous access to the anti-vi-
ral agents (problematic are patients without stable
residency or immigrants from developing coun-
tries without legal status).
The objective of therapy is to suppress HBV
replication in a sustained manner to prevent pro-
gression towards cirrhosis and HCC. Thus, the
main goal of the therapy is HBV DNA reduction
below the limit of detection (10 IU/ ml).As known
from the HIV field, sustained viral abatement is
necessary to avoid the risk of antiviral resistance.
However, the expected end-points of treatment
depend on the selected therapy (interferon versus
nucleos(t)ide analogues: NUCs) and accordingly,
three levels of therapy goals in CHB are obtaina-
ble: 1) complete and definitive remission of CHB
characterised by HBsAg loss (± anti-HBs serocon-
version) 2) seroconversion to anti-HBe in HBeAg
positive CHBwith loss of HBeAg and 3) sustained
undetectable HBV DNA while on treatment.
Table 4
Available drugs to treat CHB in Switzerland as of June 2009.
Active substance Trade name Registered indication in CH
Pegylated interferon-a
2a
Pegasys
®
All stages of CHB
Lamivudine Zeffix
®
Treatment-naïve CHB
Telbivudine Sebivo
®
Treatment-naïve CHB
Entecavir Baraclude
®
Treatment-naïve CHB
Adefovir Hepsera
®
Only if treatment failure with NUC
Tenofovir Viread
®
HIV infection and/or HIV/HBV co-infection
Tenofovir+Emtricitabine Truvada
®
HIV infection and/or HIV/HBV co-infection
The treatments: how to treat
At the time of writing, seven drugs are availa-
ble for treatment of CHB in Switzerland
(table 4): pegylated interferon-a
2a
(PEG-IFN-a
2a
)
(Pegasys
®
) and three classes of nucleos(t)ide ana-
logues (NUCs): 1) L-nucleosides analogues, com-
prising lamivudine (Zeffix
®
) and telbivudine (Se-
bivo
®
), 2) deoxyguanosine analogues, represented
by entecavir (Baraclude
®
) and 3) acyclic nucleo-
side phosphonates, such as adefovir dipivoxil
(Hepsera
®
) and tenofovir disoproxil fumarate
(Viread
®
), the latter also available in combination
with emtricitabine in a single pill (Truvada
®
).
The long-term efficacy of these drugs di-
verges because of the different drug-resistance
patterns. Based on the available drugs, the treat-
ment approach can be divided into two categories:
treatment of finite duration with PEG-IFN-a
2a
and long-term treatment with NUCs.
In Switzerland the licensed indication for
NUCs differs from drug to drug and also from
other countries (hence the need to adapt interna-
tional guidelines). At the time of writing lamivu-
dine, telbivudine and entecavir are approved as
first-line therapy for treatment-naïve CHB,
whereas adefovir is a second-line treatment, i.e.
approved – so far – only for CHB with previous
treatment failure under a NUC. Tenofovir is for
the moment licensed only in case of human immu-
nodeficiency virus (HIV) infection and in HIV-
HBV co-infected patients for the treatment of
HIV infection. Tenofovir cannot be prescribed in
HBV monoinfected patients unless a specific per-
mission from the patient’s health insurance has
been granted. PEG-IFN-a
2a
is approved without
limitations: its use is more favourable in HBeAg-
positive patients, who have the best chance of
seroconversion to anti-HBe. PEG-IFN-a
2a
should
be used with caution in patients with cirrhosis, and
is even contraindicated in those with decompen-
sated cirrhosis (see below). HBeAg-negative
chronic hepatitis B may also be treated with PEG-
IFN-a
2a
if histologically-proven, moderate-to-se-
vere necro-inflammatory activity or fibrosis are
present. However, the chances of response in this
form are lower.
The HBeAg seroconversion rate after one
year of treatment for all NUCs is around 20%, in-
creasing to up to 33% with PEG-IFN-a
2a
[2]. In
HBeAg-negative patients, the on-treatment viro-
logical response (suppression of HBV DNA) can
be obtained in 60-90% at one year, irrespectively
of the regimen. The ultimate goal of HBsAg loss
can be achieved only in about 8%with PEG-IFN-
a
2a
and only in some very rare cases with NUCs.
Lamivudine has the lowest barrier to viral resis-
tance followed by telbivudine. Adefovir has an in-
termediate efficacy (barrier to resistance) and is
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ideal candidates for first-line treatment of CHB
and are also the treatment of choice whenever re-
sistance occurs, in which case, however, the spe-
cific resistance profile of each drug should be
taken into consideration for adjusting the regimen
(table 6).
Finally, predictors of response to treatment
should be taken into consideration when choosing
a therapy for HBeAg-positive CHB (PEG-IFN-
a
2a
versusNUCs) (see table 5).The choice whether
to treat with PEG-IFN-a
2a
or NUCs is certainly
not easy. PEG-IFN-a
2a
should be considered as
first-line treatment because of its higher chance of
inducing HBeAg and even HBsAg seroconversion
(table 8 compares pros and cons of PEG-IFN-a
2a
versus NUCs).
Table 5
Pre-treatment
and on-treatment
predictors.
Pre-treatment predictors for HBe seroconversion On-treatment predictors for treatment response
Pegylated
interferon-a
2a
Low HBV viraemia (<10
7
IU/ml)
High serum ALT (>3 times ULN)
High activity score in histology
HBV genotypes A and B may respond better
than genotypes C and D
HBV DNA decrease to <20,000 IU/ml at 12 weeks
Kinetics of serum HBsAg might be useful but is not
sufficiently studied
NUCs Low HBV viraemia (<10
7
IU/ml)
High serum ALT (>3 times ULN)
High activity score in histology
Undetectable HBV DNA
Table 6
Viral mutations and cross-resistances to the different anti-viral agents
(S: sensitive; I: intermediate; R: resistant). Adapted from [1].
HBV variant Levels of susceptibility
LAM LdT ETV ADV TDF
Wild type S S S S S
M204I R R I/R S S
L180M + M204V R R I S S
A181T/V I S S R S
N236T S S S R I
L180M + M204V/I ± I169T ±V173L ±M250V
R R R S S
L180M + M204V/I ±T184G ± S202I/G
R R R S S
Treatment failure
Three types of treatment failure can be iden-
tified: 1) primary non-responders (<1 log
10
drop of
HBV DNA at week 12 of therapy), 2) partial viro-
logical responders (with slow decline of viraemia
towards still detectable levels) 3) virological break-
through (initial response and reappearance of
serum HBV viraemia while still on treatment).
In all patients with treatment failure the most
important initial step is to check for treatment
compliance, as this is the major reason for treat-
ment failure. If compliance is certain and true re-
sistance is suspected, genotypic resistance testing
should be carried out and rescue therapy initiated
with the most effective antiviral agent, in order to
avoid the risk of selecting multiple drug-resistant
viral strains. The rescue therapy may be a switch
or add-on of a more potent NUC. Resistant viral
strains can present with cross-resistance between
drugs (table 6). As an example, the resistance pat-
tern of lamivudine is similar to telbivudine, and
therefore the chances of success when treating
lamivudine resistance with telbivudine are low. In
Switzerland, the licensed rescue drugs comprise
adefovir and entecavir, however, based on the re-
sistance profile of lamivudine and telbivudine, the
most potent, ideal agent is tenofovir (table 6 and
table 7).
Table 7
Treatment adjustment in case of resistance to antivirals.
If resistance to: Treatment Adjustment:
Lamivudine (LAM) Switch to Adefovir or Tenofovir
Adefovir (ADF) If a N236T mutation is present add LAM or ETV or LdT or
switch to Tenofovir combined with Emtricitabine (Truvada
®
); if a
A181V/T mutation is present, add ETV or switch to Tenofovir
Telbivudine (LdT) Add Tenofovir
Entecavir (ETV) Add Tenofovir
Tenofovir (TDF) Add LAM or ETV or Emtricitabine (Truvada
®
)
Treatment of special patients groups
Cirrhosis
Fibrosis (≥F2) or cirrhosis constitute a definite
indication for treatment. Patients with compen-
sated or decompensated cirrhosis must be treated
with NUCs. Although PEG-IFN-a
2a
can be used
for the treatment of compensated cirrhosis, albeit
with some caution, it is definitely contraindicated
in cases of decompensated cirrhosis. In cirrhotics
it is reasonable to use one of the most potent anti-
the most expensive drug. The most potent antivi-
rals with the highest barrier for resistance muta-
tions are tenofovir and entecavir: both may be the
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viral drugs (entecavir or tenofovir) to avoid he-
patic decompensation due to hepatic flare when a
resistant strain is selected. Patients need to be
closely followed, because HBV DNA should be
suppressed as early as possible and in a sustained
manner.
Liver transplant patients
Patients with CHB and end-stage liver dis-
ease, for whom an indication to liver transplant
has been established, should be treated with
NUCs, regardless of ALT and HBV DNA levels.
It is of enormous importance that patients do not
present an active HBV infection at the moment of
transplantation because the risk of re-infection of
the grafted liver is high. Ideally, serumHBVDNA
must be undetectable at transplantation. After
transplantation, long-term combination treatment
with NUCs and anti-HBs immunoglobulins
(HBIG) reduces the risk of HBV re-infection of
the graft virtually to nil. Because of the high costs
of HBIG, there is a trend today to withdraw them
at one point post-LT and treat either with a potent
antiviral alone or a NUCs combination therapy.
However, after discontinuation of HBIG, i.e. in
cases with NUCs prophylaxis alone, the re-infec-
tion rate at 4 years is 9% [10], which is fairly high
compared to 0% that could be reached with the
combined therapy.
Health care workers
EASL guidelines suggest that healthcare
workers, especially those involved in invasive
procedures, should be treated with a potent NUC,
if HBV viraemia ≥2000 IU/ml. Undetectable
HBV DNA is a requirement to minimise the risk
of HBV transmission to patients.
Acute hepatitis B
In immunocompetent individuals, acute HBV
infection recovers spontaneously with HBsAg se-
roconversion in more than 95% of cases. Treat-
ment with antivirals is not indicated.
Coinfection with hepatitis delta virus (HDV)
Interferon is the only efficient drug for repli-
cative HDV infection and sometimes therapies
longer than one year are necessary. HDV clear-
ance and even HBsAg seroconversion can be ob-
tained with PEG-IFN-a
2a
.
Coinfection with hepatitis C virus (HCV)
In HCV/HBV co-infected patients, usually
one virus dominates over the other, often with
predominance of HCV. If HCV is viraemic, treat-
ment with PEG-IFN-a
2a
and ribavirin should be
given. If HCV is cleared (sustained virological re-
sponse), HBV can reactivate and thus needs to be
closely monitored and eventually treated with
NUCs.
Coinfection with HIV
HIV-HBV coinfected patients are at higher
risk for cirrhosis and HCC than HBV mono-in-
fected patients. The indications of therapy are the
same as in HBV mono-infected patients. If a
highly active retroviral therapy or an anti-HBV
therapy is necessary, treatment should always tar-
get both viruses to avoid the development of viral
resistance, as some NUCs (lamivudine, entecavir,
tenofovir, emtricitabine) act on both viruses to dif-
ferent degrees [11, 12]. If, however, there is need
to treat HBV without interacting with HIV, ade-
fovir and telbivudine are agents without activity
on HIV replication and are the treatment of
choice.
Children
The majority of children presents with CHB
in an immune tolerant phase and should not be
treated. Only conventional interferon-a, lamivu-
dine and adefovir have been evaluated for safety
and efficacy, which are comparable to adults.
Pregnancy
Telbivudine and tenofovir are characterised by
the FDA as category B drugs, whereas lamivudine,
adefovir and entecavir are listed as category C.An-
tiviral treatment is to be avoided until the third
trimester of pregnancy. Studies show that in pa-
tients with high viraemia lamivudine reduces the
risk of intra-uterine and perinatal transmission of
HBV if given in addition to passive and active vac-
cination by HBIG and HBV vaccination [13].
Immunosuppressed patients
Patients undergoing immunosuppressive
treatment or chemotherapy, even for short-term
courses, should be screened for HBsAg, anti-HBc,
and anti-HBs (andHBVDNA if HBsAg is already
positive) because of the high risk of viral reactiva-
Table 8
Advantages and
disadvantages of
PEG-IFN-a
2a
and
NUCs for the
treatment of chronic
hepatitis B.
Pegylated Interferon-a
2a
Nucleos(t)ide analogues
Tolerability Side effects may be important and can lead to
dose reduction or treatment discontinuation
Usually well tolerated and rare side effects
Treatment duration 48 weeks Unlimited
HBeAg seroconversion 33% 20%
HBsAg seroconversion Up to 8% Very rare
Antiviral resistance Absent Significant with lamivudine; less important with adefovir
or telbivudine; very rare with entecavir and so far not
described for tenofovir
Use in cirrhosis Limited use (only in compensated cirrhosis) Ideal indication, because they can prevent decompensation
159
SWISS MED WKLY 2010 ; 140 ( 11–12 ) : 154–159 · www.smw.ch
tion with hepatic flares [14]. In HBV naïve pa-
tients (all serum markers negative), vaccination
should be given prior to immunosuppressive treat-
ment. HBsAg-positive patients (inactive carriers)
should be tested for HBV DNA levels and treated
with lamivudine, probably the best candidate be-
cause due to its low price and negligible side ef-
fects. This pre-emptive therapy should be main-
tained for up to 12 months after cessation of im-
mune suppression or chemotherapy. Anti-HBc
positive carriers (HBsAg negative ± anti-HBs, past
infection) should only be closely followed without
pre-emptive anti-HBV treatment. HBV viraemia
and ALT levels should be tested bimonthly and in
case of HBV DNA reactivation (even without
ALT elevation) a potent NUC should be urgently
added to avoid hepatic flares.
Patients with chronic renal failure
Patients with chronic renal failure and under-
going dialysis can be treated with NUC but dos-
age needs to be adapted to renal function.Consist-
ent data are available for lamivudine and may be
the safest choice in patients with impaired renal
function. Adefovir and tenofovir should be used
with caution due to possible effects on renal func-
tion. For kidney transplant recipients the best
drugs may be lamivudine or entecavir.
In conclusion, HBV is a dynamic infection
with different phases, which determine the differ-
ent attitude towards antiviral therapy. HBV virae-
mia, ALT levels and liver histology are crucial pa-
rameters for treatment indication. However, due
to the increasing availability of antivirals and con-
comitant growing emergence of drug resistance
strains the management of CHB has become com-
plex. The most potent antiviral drugs are the best
choice to start therapy but, due to registration is-
sues, in Switzerland only few drugs for first-line
treatment are available.Therefore, even if the new
EASL guidelines help to facilitate the manage-
ment of CHB, it may be idealistic to believe that a
“one-size-fits-all algorithm” could exist. The situ-
ation may change in the future, of course, depend-
ing on the evolution of the Swiss official recom-
mendations.
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